StockData
CytoDyn Inc. logo

CytoDyn Inc. (CYDY) stock

CYDYOTCPharmaceutical PreparationsFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 14, 2026Score 4/30
$0.25+0.02 (+9.53%)

Close on Oct 19, 2026Market cap $345.56MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Aug 31, 2026

Valuation

Market cap
$345.56M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$57.10M
EPS, diluted
-$0.04
Book value per share
-$0.07
Diluted shares
1.38B

Trading

Previous close
$0.23
Open
$0.23
Day's range
$0.23 – $0.29
Volume
6,475,195
Average volume (20 days)
1,921,225

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodCYDYS&P 500DifferenceCYDY per yearS&P 500 per year
1 month+17.0%+0.6%+16.3 pts
3 months+17.7%+3.4%+14.3 pts
Year to date-10.7%+13.3%−24.0 pts
1 year-6.3%+16.6%−22.9 pts
3 years+56.3%+86.4%−30.1 pts+16.0%+23.1%
5 years-82.1%+81.9%−164.0 pts-29.1%+12.7%
10 years-62.1%+318.9%−381.0 pts-9.3%+15.4%

Fifteen years at a glance

Fiscal years 2012 to 2026 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$40.21M

Net income

-$57.10M

EPS, diluted

-$0.04

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases CytoDyn filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About CytoDyn

Pharmaceutical Preparations

CytoDyn Inc. is a clinical-stage biotechnology firm that focuses on developing and potentially commercializing targeted therapies for oncology indications. Its primary investigational asset is leronlimab, a humanized monoclonal antibody designed to bind the CCR5 receptor, which is associated with tumor development, cellular migration, and immune modulation. The company investigates leronlimab primarily for solid tumors, including relapsed or refractory metastatic colorectal cancer and metastatic triple-negative breast cancer, alongside preclinical evaluations for glioblastoma multiforme. As a development-stage biopharmaceutical organization without approved commercial products, CytoDyn does not sell therapies to conventional commercial customers; instead, its clinical programs serve cancer patients enrolled in trials and expanded access protocols.

Company profile, executives and history

CytoDyn stock: common questions

What is CytoDyn's stock price?

CYDY closed at $0.25 on Oct 19, 2026, up 9.53% on the day.

What is CytoDyn's market cap?

CytoDyn was worth $345.56M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is CYDY's P/E ratio?

CytoDyn lost money over the twelve months to Aug 31, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.

Does CytoDyn pay a dividend?

No. CytoDyn has not paid a cash dividend over the last twelve months.

How has CYDY stock performed over the past year?

Including dividends, CYDY returned -6.3% over the past year, against +16.6% for the S&P 500.

Who are CytoDyn's competitors?

Companies most similar to CytoDyn by business, industry and size include CTMX, CBIO, SNDX, CRBP, CNTX.

See a number that looks wrong?